Latham-based Institute for Clinical Pharmacodynamics, which recently announced the relocation of its Capital Region office to downtown Schenectady, is planning to increase its staff of pharmacists, doctors, researchers and lab technicians to over 20 employees in the next few years.
According to Mayor Gary McCarthy, “The new $8 million mixed-use office and residential complex at 242 Broadway will be another great asset to the fast-growing downtown of Schenectady.”
The company started in 2004 and is based in both Buffalo and Schenectady.
When Dr. Paul Ambrose was asked why ICPD chose Schenectady as their new office and laboratory, he responded that they were looking for places to expand their business around the Albany area.
He shared that there are “two criteria in (their) selection.” One is a vibrant place, as they tend to view themselves as a relatively young company. The second — and more important, according to Ambrose — is that they want to find a pleasant place, where people who visit from around the world can enjoy their stays. According to Ambrose, “Unlike other cities, Schenectady is very convenient for our visitors. The city has movie theaters and restaurants in a walking distance from our new office.”
Many of these visitors will consist of visiting scientists and people from various drug companies that ICPD is working with. For example, Ambrose shared how ICPD has visitors from Japan on a regular basis, as well as frequent visitors from Europe.
ICPD views itself as a unique and new company, according to Ambrose. He shared that they focus on drug development, mostly in factitious disease drug development.
When asked if ICPD plans on offering research opportunities to students, Ambrose stated that one of ICPD’s missions is education. “We are very interested in education on a variety of levels. We take postdoctoral scholars and fellow positions here at ICPD for people who are interested in drug development, especially in areas of translation medicine, which is the area that we are working in. Physicians and visiting scholars come to ICPD from across the countries. We will also have a young physician join us next month for a yearn” he responded.
He stated how once the laboratory in Schenectady is developed, there are definite possibilities for Union students to explore areas in translational medicine.
ICPD has two main missions: one is to improve the way drugs are developed and used in the care of patients worldwide, while, the other is education. They have a 24-month ICPD Research Fellowship Program, which is intended to provide medical or pharmacy school graduates with the skills necessary to enhance their research careers in academia and the pharmaceutical industry.
Mentors from editorial board members of prominent journals guide young pharmacists, physicians and students to the area of translation medicines.
ICPD works on a variety of projects, one specifically involving antibiotics and infectious forecast. They attempt to extract information from very early stages in drug development via different models, for example: in vitro PK-PD infection models. They work with everything from tuberculosis to resistant bacteria. Ambrose stated how ICPD’s goal is to prevent bacteria over resistance and make sure drugs are optimally dosed.
On the topic of the future of biotechnology, Ambrose shared how biotechnology has become hot again, specifically in infectious diseases. He revealed that there are a lot of investments from venture capitalists.
Ambrose spoke about the clear shift in government attitudes in the United States and European countries regarding antibiotics. Governments and Congresses are recognizing the emergent public health threat in diseases and bacteria.
According to The Centers for Disease Control and Prevention, “the antibiotic-resistant infections account for at least $20 billion in excess direct health care costs and up to $35 billion in lost productivity due to hospitalizations and sick days each year.”
Ambrose emphasized the importance of mathematics in the future of biotech development. He stated how mathematics is “becoming more and more important to drug development.” To him, it is a tool that integrates information with sources miraculously.